Literature DB >> 28736375

[Expression of vasohibin-1 and MACC1 in lung squamous cell carcinoma and their clinicopathological significance].

Shi-Wu Wu1, Yi-Chao Wang, Hong-Fei Ci, Yi-Sheng Tao.   

Abstract

OBJECTIVE: To investigate the expressions of vasohibin-1 and MACC1 in lung squamous cell carcinoma (LSCC) and their associations with the clinicopathological characteristics of the patients.
METHODS: The expressions of vasohibin-1 and MACC1 proteins were examined with immunohistochemistry in 160 LSCC tissues and 80 normal lung tissues.
RESULTS: The positivity rates of vasohibin-1 and MACC1 proteins were 59.4% and 11.3% in LSCC tissues, respectively, which were significantly higher than the rates in normal lung tissues (57.5% and 8.8%, respectively; P<0.05). The expressions of vasohibin-1 and MACC1 proteins were significantly correlated with the tumor grades, lymph node metastasis, and TNM stages (all P<0.05). Spearman correlation analysis indicated a positive correlation between vasohibin-1 expression and MACC1 expressions (P<0.001). Kaplan-Meier survival analysis showed that LSCC patients with a positive expression of vasohibin-1 had significantly shorter overall survival time than those negative for vasohibin-1; the overall survival time was also significantly shorter in patients positive for MACC1 than in those negative for MACC1 (both P<0.05). Multivariate COX regression analysis indicated that positive expressions of vasohibin-1 and MACC1 protein and TNM stage were independent prognostic factors of LSCC.
CONCLUSION: Aberrant expressions of vasohibin-1 and MACC1 may participate in the development and promote invasion and metastasis of LSCC. The combined detection of vasohibin-1 and MACC1 expression may provide important evidence for predicting the progression and prognosis of LSCC.

Entities:  

Year:  2017        PMID: 28736375      PMCID: PMC6765526     

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  21 in total

1.  MACC1 controls Met: what a difference an Sp1 site makes.

Authors:  Ulrike Stein; Janice Smith; Wolfgang Walther; Franziska Arlt
Journal:  Cell Cycle       Date:  2009-08-13       Impact factor: 4.534

2.  Recombinant adenovirus encoding vasohibin prevents tumor angiogenesis and inhibits tumor growth.

Authors:  Dajiang Li; Kun Zhou; Shuguang Wang; Zhong Shi; Zhao Yang
Journal:  Cancer Sci       Date:  2009-10-06       Impact factor: 6.716

3.  Metastasis-associated in colon cancer-1 upregulates vascular endothelial growth factor-C/D to promote lymphangiogenesis in human gastric cancer.

Authors:  Li Sun; Jiangman Duan; Yaqi Jiang; Lin Wang; Na Huang; Li Lin; Yulin Liao; Wangjun Liao
Journal:  Cancer Lett       Date:  2014-11-18       Impact factor: 8.679

4.  Lung cancer: New biological insights and recent therapeutic advances.

Authors:  Suresh S Ramalingam; Taofeek K Owonikoko; Fadlo R Khuri
Journal:  CA Cancer J Clin       Date:  2011-02-08       Impact factor: 508.702

5.  Global cancer statistics, 2012.

Authors:  Lindsey A Torre; Freddie Bray; Rebecca L Siegel; Jacques Ferlay; Joannie Lortet-Tieulent; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-02-04       Impact factor: 508.702

6.  The prognostic significance of vasohibin-1 expression in patients with upper urinary tract urothelial carcinoma.

Authors:  Yasumasa Miyazaki; Takeo Kosaka; Shuji Mikami; Eiji Kikuchi; Nobuyuki Tanaka; Takahiro Maeda; Masaru Ishida; Akira Miyajima; Ken Nakagawa; Yasunori Okada; Yasufumi Sato; Mototsugu Oya
Journal:  Clin Cancer Res       Date:  2012-06-06       Impact factor: 12.531

7.  Distinctive localization and opposed roles of vasohibin-1 and vasohibin-2 in the regulation of angiogenesis.

Authors:  Hiroshi Kimura; Hiroki Miyashita; Yasuhiro Suzuki; Miho Kobayashi; Kazuhide Watanabe; Hikaru Sonoda; Hideki Ohta; Takashi Fujiwara; Tooru Shimosegawa; Yasufumi Sato
Journal:  Blood       Date:  2009-02-09       Impact factor: 22.113

8.  Vasohibin-1 is identified as a master-regulator of endothelial cell apoptosis using gene network analysis.

Authors:  Muna Affara; Debbie Sanders; Hiromitsu Araki; Yoshinori Tamada; Benjamin J Dunmore; Sally Humphreys; Seiya Imoto; Christopher Savoie; Satoru Miyano; Satoru Kuhara; David Jeffries; Cristin Print; D Stephen Charnock-Jones
Journal:  BMC Genomics       Date:  2013-01-16       Impact factor: 3.969

9.  Aberrant expression of CD133 in non-small cell lung cancer and its relationship to vasculogenic mimicry.

Authors:  Shiwu Wu; Lan Yu; Danna Wang; Lei Zhou; Zenong Cheng; Damin Chai; Li Ma; Yisheng Tao
Journal:  BMC Cancer       Date:  2012-11-21       Impact factor: 4.430

10.  MACC1 promotes carcinogenesis of colorectal cancer via β-catenin signaling pathway.

Authors:  Tiantian Zhen; Sujuan Dai; Hui Li; Yang Yang; Lili Kang; Huijuan Shi; Fenfen Zhang; Dongjie Yang; Shirong Cai; Yulong He; Yingjie Liang; Anjia Han
Journal:  Oncotarget       Date:  2014-06-15
View more
  1 in total

1.  MicroRNA-598 Inhibits Cell Proliferation and Invasion of Glioblastoma by Directly Targeting Metastasis Associated in Colon Cancer-1 (MACC1).

Authors:  Ning Wang; Yang Zhang; Huaxin Liang
Journal:  Oncol Res       Date:  2018-02-14       Impact factor: 5.574

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.